Spray Glucagon vs Injections: Key Product Attributes Compared
Abstract: Spray glucagon offers a needle-free alternative to traditional injections for severe hypoglycemia, leveraging intranasal delivery for rapid absorption. Compared to injectable forms, spray formulations demonstrate comparable efficacy with improved ease of use and reduced needle-stick risk. Market trends indicate a shift toward patient-centric devices, with brands like Baqsimi leading. Key product attributes include bioavailability, onset time, and storage stability. Regulatory approvals (FDA, EMA) and manufacturing GMP certifications are critical for quality assurance. Selection criteria prioritize device reliability, dosage accuracy, and cold-chain logistics. The peptide industry shows robust growth, driven by diabetes prevalence and innovation in non-invasive delivery systems.